These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20067604)

  • 21. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
    Mayer EL
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
    [No Abstract]   [Full Text] [Related]  

  • 22. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
    Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
    Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical development of CDK4/6 inhibitor for breast cancer.
    Iwata H
    Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
    Teh JLF; Aplin AE
    Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
    Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
    Finn RS; Aleshin A; Slamon DJ
    Breast Cancer Res; 2016 Feb; 18(1):17. PubMed ID: 26857361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDK4/6 blockade in breast cancer: current experience and future perspectives.
    Zardavas D; Pondé N; Tryfonidis K
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of CDK4/6 Inhibition in Breast Cancer.
    Murphy CG; Dickler MN
    Oncologist; 2015 May; 20(5):483-90. PubMed ID: 25876993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
    Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
    Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
    Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
    Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
    Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
    JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER
    Petroni G; Buqué A; Yamazaki T; Bloy N; Liberto MD; Chen-Kiang S; Formenti SC; Galluzzi L
    Clin Cancer Res; 2021 Apr; 27(7):1855-1863. PubMed ID: 33495311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.